drugset / Trial / NCT01011205

Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation

NCT01011205

Phase 3 Completed 893 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

Comparison of 3 dosing regimens of Advagraf to determine if there is a dosing regimen which may have the potential to cause fewer kidney problems.

Timeline

Start
2009-09-30
Primary completion
2013-01-04
Completion
2013-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Basiliximab Monoclonal antibody Intravenous
Subject Tacrolimus Small molecule
Background Mycophenolate Mofetil Small molecule

Indications

No indication recorded.